Amryt Pharma is quoted on the London Stock Exchange’s AIM Market and the Irish Stock Exchange’s Euronext Market.

Major Shareholders

Major shareholders

Major shareholders are as follows (interest as at 2 January 2020).

Name Number of shares % of issued share capital
Funds managed by Athyrium
Capital Management, LP
42,883,097 27.8%
Novelion Therapeutics Inc. 14,040,250 9.09%
Edgepoint Investment Group Inc. 12,126,650 7.85%
Funds managed by Highbridge Capital Management LLC
Software AG-Stiftung 10,212,153 6.61%
AXA Investment Management 6,494,164 4.20%
Funds managed by UBS O’Connor LLC 6,220,174 4.03%

The issued share capital of the Company is comprised of 159,363,543 ordinary Shares, of which 4,864,656 are held as treasury shares. Accordingly the total number of voting rights in the Company is 154,498,887. This figure may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure Guidance and Transparency Rules.

Pursuant to the AIM rules, and insofar as the Company is aware, as at 2 January 2020, 31.91% of the Company’s issued share capital is not in public hands.

Restrictions: there are no restrictions on the transfer of Ordinary Shares.
Takeover Code: the Company is subject to the City Code on Takeovers and Mergers.